NEPH vs NX vs CNMD vs APOG

For growth investors, Quanex Building Products Corporation (NX) is the stronger pick with 43.

8% revenue growth year-over-year, versus 3. 2% for Apogee Enterprises, Inc. (APOG). Apogee Enterprises, Inc. (APOG) offers the better valuation at 14. 5x trailing P/E (10. 7x forward), making it the more compelling value choice. Analysts rate Quanex Building Products Corporation (NX) a "Hold" — based on 10 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Apogee Enterprises, Inc.

(APOG) is the cheapest at 14. 5x versus Nephros, Inc. at 32. 0x. On forward P/E, CONMED Corporation is actually cheaper at 8. 4x — notably different from the trailing picture, reflecting expected earnings growth. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: CONMED Corporation wins at 0. 23x versus Apogee Enterprises, Inc. 's 0. 32x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.

Over the past 5 years, Apogee Enterprises, Inc.

(APOG) delivered a total return of +11. 1%, compared to -71. 8% for CONMED Corporation (CNMD). Over 10 years, the gap is even starker: NX returned +24. 7% versus CNMD's +3. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Nephros, Inc.

(NEPH) is the lower-risk stock at 0. 58β versus Quanex Building Products Corporation's 1. 83β — meaning NX is approximately 218% more volatile than NEPH relative to the S&P 500. On balance sheet safety, Nephros, Inc. (NEPH) carries a lower debt/equity ratio of 10% versus 118% for Quanex Building Products Corporation — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Quanex Building Products Corporation (NX) is pulling ahead at 43.

8% versus 3. 2% for Apogee Enterprises, Inc. (APOG). On earnings-per-share growth, the picture is similar: Apogee Enterprises, Inc. grew EPS -35. 2% year-over-year, compared to -703. 3% for Quanex Building Products Corporation. Over a 3-year CAGR, NEPH leads at 23. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Nephros, Inc.

(NEPH) is the more profitable company, earning 6. 4% net margin versus -13. 6% for Quanex Building Products Corporation — meaning it keeps 6. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: CNMD leads at 10. 3% versus -10. 6% for NX. At the gross margin level — before operating expenses — NEPH leads at 61. 1%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, CONMED Corporation (CNMD) is the more undervalued stock at a PEG of 0. 23x versus Apogee Enterprises, Inc. 's 0. 32x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, CONMED Corporation (CNMD) trades at 8. 4x forward P/E versus 10. 7x for Apogee Enterprises, Inc. — 2. 3x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for CNMD: 112. 2% to $78. 00.

In this comparison, APOG (2.

8% yield), CNMD (2. 2% yield), NX (1. 6% yield) pay a dividend. NEPH does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Nephros, Inc.

(NEPH) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 58)). Quanex Building Products Corporation (NX) carries a higher beta of 1. 83 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (NEPH: +11. 7%, NX: +24. 7%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (NEPH (Healthcare) and NX (Industrials) and CNMD (Healthcare) and APOG (Industrials)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: NEPH is a small-cap high-growth stock; NX is a small-cap high-growth stock; CNMD is a small-cap quality compounder stock; APOG is a small-cap deep-value stock. NX, CNMD, APOG pay a dividend while NEPH does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.